Mifepristone as treatment of recurrent progesterone receptor-positive uterine leiomyosarcoma

Obstetrics and Gynecology

Volumn 109, Issue 2 PART 2 SUPPL., 2007, Pages 512-514

  Koivisto Korander, Riitta ^a   Leminen, Arto ^a   Heikinheimo, Oskari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; IFOSFAMIDE; MIFEPRISTONE; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYTOREDUCTIVE SURGERY; DRUG DOSE INCREASE; FEMALE; HUMAN; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; LABORATORY TEST; LEIOMYOSARCOMA; LIVER FUNCTION TEST; LIVER METASTASIS; LUNG METASTASIS; NIGHT SWEAT; PELVIS CANCER; PELVIS METASTASIS; PRIORITY JOURNAL; SALPINGOOOPHORECTOMY; SIDE EFFECT; THYROID FUNCTION TEST; TUMOR VOLUME; UTERUS LEIOMYOSARCOMA; UTERUS TUMOR;

DIAGNOSIS, DIFFERENTIAL; FEMALE; HORMONE ANTAGONISTS; HUMANS; LEIOMYOSARCOMA; MIDDLE AGED; MIFEPRISTONE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; RECEPTORS, PROGESTERONE; UTERINE NEOPLASMS;

EID: 33846408662     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000223228.23289.0f     Document Type: Article

References (8)

1. Giuntoli RL II, Metzinger DS, DiMarco CS, Cha SS, Sloan JA, Keeney GL, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management and adjuvant therapy. Gynecol Oncol 2003;89:460-9.
2. Kanjeekal S, Chambers A, Fung Kee Fung M, Verma S. Systemic therapy for advanced uterine sarcoma: a systemic review of the literature. Gynecol Oncol 2005;97:624-37.
3. Wade K, Quinn MA, Hammond I, Williams K, Cauchi M. Uterine sarcoma: steroid receptors and response to hormonal therapy. Gynecol Oncol 1990;39:364-7.
4. Akhan SE, Yavuz E, Tecer A, Iyibozcurt CA, Topuz S, Tuzlali S, et al. The expression of Ki-67, P53, estrogen and progesterone receptors affecting survival in uterine leiomyosarcomas: a clinicopathologic study. Gynecol Oncol 2005;99:36-42.
5. Steinauer J, Pritts EA, Jacson R, Jacoby AF. Systematic review of mifepristone for the treatment of uterine leiomyomata. Obstet Gynecol 2004;103:1331-6.
6. Liote F, Lestang P, Pelissier-Langbort C, Le Bozec C, Quillard A, Bellaiche L, et al. Disseminated leiomyosarcoma of the bone with progesterone receptors. Rev Rhum Engl Ed 1995;62:57-8.
7. Heikinheimo O, Ranta S, Grunberg S, Lähteenmäki P, Spitz I. Alterations in the pituitary-thyroid and pituitary-adrenal axis: consequences of long-term mifepristone treatment. Metabolism 1997;46:292-6.
8. Koide SS. Mifepristone: auxiliary therapeutic use in cancer and related disorders. J Reprod Med 1998;43:551-60.